» Articles » PMID: 37293292

Bayesian Networks and Imaging-derived Phenotypes Highlight the Role of Fat Deposition in COVID-19 Hospitalisation Risk

Overview
Journal Front Bioinform
Specialty Biology
Date 2023 Jun 9
PMID 37293292
Authors
Affiliations
Soon will be listed here.
Abstract

Obesity is a significant risk factor for adverse outcomes following coronavirus infection (COVID-19). However, BMI fails to capture differences in the body fat distribution, the critical driver of metabolic health. Conventional statistical methodologies lack functionality to investigate the between fat distribution and disease outcomes. We applied Bayesian network (BN) modelling to explore the mechanistic link between body fat deposition and hospitalisation risk in 459 participants with COVID-19 (395 non-hospitalised and 64 hospitalised). MRI-derived measures of visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and liver fat were included. Conditional probability queries were performed to estimate the probability of hospitalisation after fixing the value of specific network variables. The probability of hospitalisation was 18% higher in people living with obesity than those with normal weight, with elevated VAT being the primary determinant of obesity-related risk. Across all BMI categories, elevated VAT and liver fat (>10%) were associated with a 39% mean increase in the probability of hospitalisation. Among those with normal weight, reducing liver fat content from >10% to <5% reduced hospitalisation risk by 29%. Body fat distribution is a critical determinant of COVID-19 hospitalisation risk. BN modelling and probabilistic inferences assist our understanding of the mechanistic associations between imaging-derived phenotypes and COVID-19 hospitalisation risk.

Citing Articles

Rationale and design of the multi organ inflammation with serial testing study: a comprehensive assessment of functional and structural abnormalities in patients with recovered COVID-19.

Paterson D, White J, Beaulieu C, Sherrington R, Prado C, Tandon P Front Med (Lausanne). 2024; 11:1392169.

PMID: 39114821 PMC: 11303169. DOI: 10.3389/fmed.2024.1392169.

References
1.
Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M . Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021; 54(9):1150-1161. PMC: 9292692. DOI: 10.1111/apt.16608. View

2.
Colleluori G, Graciotti L, Pesaresi M, Di Vincenzo A, Perugini J, Di Mercurio E . Visceral fat inflammation and fat embolism are associated with lung's lipidic hyaline membranes in subjects with COVID-19. Int J Obes (Lond). 2022; 46(5):1009-1017. PMC: 8790008. DOI: 10.1038/s41366-022-01071-w. View

3.
Bunnell K, Thaweethai T, Buckless C, Shinnick D, Torriani M, Foulkes A . Body composition predictors of outcome in patients with COVID-19. Int J Obes (Lond). 2021; 45(10):2238-2243. PMC: 8267764. DOI: 10.1038/s41366-021-00907-1. View

4.
Ross R, Neeland I, Yamashita S, Shai I, Seidell J, Magni P . Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat Rev Endocrinol. 2020; 16(3):177-189. PMC: 7027970. DOI: 10.1038/s41574-019-0310-7. View

5.
Zaffina C, Wyttenbach R, Pagnamenta A, Grasso R, Biroli M, Del Grande F . Body composition assessment: comparison of quantitative values between magnetic resonance imaging and computed tomography. Quant Imaging Med Surg. 2022; 12(2):1450-1466. PMC: 8739087. DOI: 10.21037/qims-21-619. View